Disposition of radiolabeled imipenem and cilastatin in normal human volunteers
Open Access
- 1 November 1984
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 26 (5) , 707-714
- https://doi.org/10.1128/aac.26.5.707
Abstract
In the first of two successive studies, four healthy male subjects received 500 mg of 14C-labeled imipenem alone and together with 500 mg of unlabeled cilastatin sodium. In the second study, the same subjects were given 250 mg of 14C-labeled cilastatin sodium alone and together with 250 and 1,000 mg of cold imipenem. Concentrations of imipenem and cilastatin in plasma, urine, and feces were assayed by high-pressure liquid chromatography and radiometry. Plasma concentrations of imipenem assayed radiometrically were higher than those measured by high-pressure liquid chromatography. In one subject studied at the end of drug administration, the open lactam metabolite of imipenem represented 9% of the radioactivity. Plasma levels of cilastatin determined by high-pressure liquid chromatography and radiometry were virtually identical. Urinary recovery of imipenem varied between 12 and 42% of the dose when that drug was given alone but increased to between 64 and 75% when administered with cilastatin sodium at a 1:1 ratio. Almost all radioactivity of imipenem was recovered in the urine within 96 h after drug administration. The open lactam metabolite, resulting from the metabolism of imipenem in the kidneys by a dipeptidase, dehydropeptidase-I, represented 80 to 90% of the effluent radioactivity when imipenem was given alone and about 20% when cilastatin sodium was coadministered. Renal excretion of cilastatin followed closely that of imipenem. Almost all of the administered radioactivity was recovered in 24 h, and about 75% of the dose was recovered as unchanged cilastatin within 6 h. The N-acetyl metabolite of cilastatin was found to represent about 12% of the total radioactivity.This publication has 7 references indexed in Scilit:
- Urinary Recovery of N -Formimidoyl Thienamycin (MK0787) as Affected by Coadministration of N -Formimidoyl Thienamycin Dehydropeptidase InhibitorsAntimicrobial Agents and Chemotherapy, 1983
- Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humansAntimicrobial Agents and Chemotherapy, 1983
- Safety and tolerance comparison of imipenem-cilastatin to cephalothin and cefazolinJournal of Antimicrobial Chemotherapy, 1983
- Thienamycin: development of imipenem-cilastatinJournal of Antimicrobial Chemotherapy, 1983
- Metabolism of Thienamycin and Related Carbapenem Antibiotics by the Renal Dipeptidase, Dehydropeptidase-IAntimicrobial Agents and Chemotherapy, 1982
- In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidimeAntimicrobial Agents and Chemotherapy, 1981
- MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activitiesAntimicrobial Agents and Chemotherapy, 1980